Variables | Survival status | Incidence density/10 000 | Crude HR (95% CI) | Adjusted HR (95% CI) | |
Censored | Event | ||||
Sex of child | |||||
Male | 357 | 22 | 17 | 1 | |
Female | 404 | 41 | 27 | 1.63 (0.97 to 2.74) | * |
Disclosure status | |||||
No | 586 | 56 | 25 | 2.35 (1.07 to 5.16) | 4.51 (1.78 to 11.45) |
Yes | 175 | 7 | 11 | 1 | 1 |
Duration of follow-up in months | |||||
≤34 | 424 | 25 | 32 | 1 | 1 |
≥35 | 337 | 38 | 18 | 0.05 (0.02 to 0.10) | 0.06 (0.02 to 0.19) |
Baseline OIs | |||||
No | 567 | 39 | 19 | 1 | 1 |
Yes | 194 | 24 | 30 | 1.47 (0.88 to 2.44) | 2.27 (1.29 to 3.99) |
Baseline CD4 count, cells/mm3 | |||||
<200 | 130 | 15 | 27 | 1.45 (0.66 to 3.15) | * |
200–350 | 158 | 8 | 15 | 0.88 (0.35 to 2.19) | * |
351–500 | 294 | 29 | 26 | 1.41 (0.71 to 2.83) | |
≥500 | 179 | 11 | 18 | 1 | |
Baseline NNRTI regimen | |||||
NVP | 544 | 44 | 20 | 1 | |
EFV | 202 | 16 | 26 | 1.54 (0.87 to 2.72) | * |
LVP/r | 15 | 3 | 62 | 4.33 (1.34 to 13.99) | * |
Year of initiations | |||||
≤2013 | 402 | 41 | 19 | 1 | |
≥2014 | 359 | 22 | 30 | 7.33 (3.74 to 14.36) | * |
Weight for age z-score | |||||
<−2 SD | 295 | 32 | 25 | 0.49 (0.17 to 1.40) | * |
−2 SD to 2 SD | 408 | 27 | 19 | 0.38 (0.13 to 1.11) | * |
>2 SD | 58 | 4 | 29 | 1 | |
Adherence | |||||
Poor (<95%) | 349 | 28 | 21 | 0.98 (0.60 to 1.63) | * |
Good (≥95%) | 412 | 35 | 23 | 1 | |
Drug substitutions | |||||
No | 494 | 31 | 22 | 1.44 (0.87 to 2.38) | * |
Yes | 267 | 32 | 22 | 1 |
*Non-significant from the Weibull Cox regression model at 5% level of significance.
ART, antiretroviral therapy; EFV, efavirenz; LPV/r, Lopinavir; NNRTI, Non-nucleoside reverse transcriptase inhibitor; NVP, nevirapine; OIs, opportunistic infections.